BIO Integration, Journal Year: 2025, Volume and Issue: 6(1)

Published: Jan. 1, 2025

Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, leading to impaired function respiratory failure. Although current treatments, such as pirfenidone nintedanib, slow progression, they fail completely halt or reverse fibrosis. Therefore, innovative therapeutic strategies are needed. Targeted drug delivery systems (TDDSs) emerging promising solutions. Biomaterials play critical roles in these enhancing specificity, availability, efficacy, while minimizing systemic toxicity. The most notable biomaterials include nanotechnology-based systems, including liposomes polymeric nanoparticles, which facilitate penetration release fibrotic tissues. Hydrogels have three-dimensional structures providing controlled sustained at inflammation sites, therefore particularly valuable PF treatment. Furthermore, biological carriers stem cells vesicles biocompatibility anti-inflammatory effects that improve outcomes. Despite the potential of clinical translation hindered several challenges, immune clearance, stability platforms, optimization retention within diseased Interdisciplinary approaches integrating precision medicine with advancements may provide solutions opening new avenues for This review discusses developments targeted PF, emphasizing importance biomaterials, mechanisms barriers involved pulmonary delivery, future perspectives overcoming limitations. ultimate goal patient outcomes revolutionizing approach treatment through advanced technologies.

Language: Английский